Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 10/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.66 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.66 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1949992 | 1.00 | FTO (0.66) | FTOMAPTMEN1KMT2AHPGD | |
| Hydrochloric Acid SCHEMBL8542650 | 0.99 | FTO (0.64) | FTOMAPTMEN1KMT2AHPGD | |
| Bromide SCHEMBL7792912 | 0.99 | FTO (0.64) | FTOMAPTMEN1KMT2AHPGD | |
| SCHEMBL30249984 | 0.91 | FTO (0.70) | FTOMAPTMEN1KMT2AHPGD | |
| SCHEMBL2334255 | 0.91 | FTO (0.70) | FTOMAPTMEN1KMT2AHPGD | |
| Hydrochloric Acid SCHEMBL1904089 | 0.90 | FTO (0.69) | FTOMAPTMEN1KMT2AHPGD | |
| Bromide SCHEMBL6999393 | 0.90 | FTO (0.69) | FTOMAPTMEN1KMT2AHPGD | |
| SCHEMBL8813305 | 0.89 | FTO (0.67) | FTOMAPTMEN1KMT2AHPGD | |
| SCHEMBL20438524 | 0.88 | FTO (0.66) | FTOMAPTMEN1KMT2AHPGD | |
| SCHEMBL4599673 | 0.88 | FTO (0.66) | FTOMAPTMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023114090-A2 | SIGNAL BOOST CASCADE ASSAY | LABSIMPLY, INC. (US) | 2023-06-22 | — | — | WO | claimed |
| US-12466855-B2 | Labeled oxytocin and method of manufacture and use | TONIX PHARMA LIMITED (IE) | 2025-11-11 | — | — | US | disclosed |
| US-20250326844-A1 | T CELL RECEPTOR MULTIMERS AND USES THEREOF | REPERTOIRE IMMUNE MEDICINES INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250319153-A1 | MAGNESIUM-CONTAINING OXYTOCIN FORMULATIONS AND METHODS OF USE | TONIX PHARMA LTD (IE) | 2025-10-16 | — | — | US | disclosed |
| US-20250130233-A1 | METHODS FOR ENHANCED BCMA IMMUNOHISTOCHEMISTRY DETECTION IN HUMAN AND MONKEY TISSUE | JANSSEN BIOTECH INC (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4541348-A2 | MAGNESIUM-CONTAINING OXYTOCIN FORMULATIONS AND METHODS OF USE | Tonix Pharma Limited (IE) | 2025-04-23 | — | — | EP | disclosed |
| EP-4522737-A2 | ENGINEERED CAS-PHI PROTEINS AND USES THEREOF | Mammoth Biosciences, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4511489-A2 | COMPOSITIONS AND METHODS FOR MODIFYING A HUMAN DYSTROPHIN GENE | Mammoth Biosciences, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-119522292-A | CRISPR RNA for detecting genetic material related to burkholderia meliodes in biological sample and using method thereof | 清迈大学 | 2025-02-25 | — | — | CN | disclosed |
| EP-3620465-B1 | IMPROVED METHODS FOR GENERATION, LABELING AND USE OF MHC MULTIMERS | DAKO DENMARK AS (DK) | 2025-02-19 | — | — | EP | disclosed |
| WO-2022216974-A1 | PEPTIDE-MHC-IMMUNOGLOBULIN MULTIMERS AND METHODS OF USE THEREOF | Repertoire Immune Medicines, Inc. (US) | 2022-10-13 | — | — | WO | disclosed |
| CN-114929872-A | Compositions and methods for treating leber hereditary optic neuropathy with NADH dehydrogenase protein | 武汉纽福斯生物科技有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022173770-A1 | PROGRAMMABLE NUCLEASES AND METHODS OF USE | MAMMOTH BIOSCIENCES, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| WO-2022165024-A1 | ELECTROPHORETIC MOBILITY SHIFT AS A MOLECULAR BEACON-BASED READOUT FOR MIRNA DETECTION | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2022-08-04 | — | — | WO | disclosed |
| CN-108350452-B | Purification of nucleic acids using copper-titanium oxides | 雅培分子公司 | 2022-07-19 | — | — | CN | disclosed |
| US-11389473-B2 | Magnesium-containing oxytocin formulations and methods of use | TONIX PHARMACEUTICALS HOLDING CORP. (US) | 2022-07-19 | — | — | US | disclosed |
| WO-2022087154-A1 | MHC CLASS II PEPTIDE MULTIMERS AND USES THEREOF | Repertoire Immune Medicines, Inc. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022061166-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF A NUCLEIC ACID | MAMMOTH BIOSCIENCES, INC. (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220072537-A1 | PROGRAMMABLE NUCLEASE COMPOSITIONS AND METHODS OF USE THEREOF | MAMMOTH BIOSCIENCES, INC. | 2022-03-10 | — | — | US | disclosed |
| US-11266711-B2 | Oxytocin compositions and methods of use | ELGAN PHARMA LTD (IL) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466855-B2 | Labeled oxytocin and method of manufacture and use | OXTR, AVPR1A, AVPR1B | FTO 1201/4885MAPT 3611/4885MEN1 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.